Disc Medicine, Inc.IRONNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

11 analysts·Moderate coverage

100%

Rating Distribution

Strong Buy

19%

Buy

1091%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 59% higher.

Bear Case

$110.00

+42%

Consensus

$122.80

+59%

Bull Case

$153.00

+98%

Price Range11 analysts

Low

Consensus

High

$110.00

$153.00

Current Target

Current Price

$77.32

Upside to Target

$45.48

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-6.72(10 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+243.90%

EPS—

FY2028

Rev+92.86%

EPS—

FY2029

Rev+67.95%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-15.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 8, 2026Morgan Stanley

Disc Medicine price target raised to $120 from $115 at Morgan Stanley

Target:$120.00

+48.3%from $80.94

Dec 8, 2025Raymond James

Disc Medicine (IRON) PT Raised to $117 at Raymond James

Target:$117.00

+21.5%from $96.32

Nov 10, 2025Truist Financial

Disc Medicine price target raised to $114 from $86 at Truist

Target:$114.00

+37.7%from $82.77

Oct 17, 2025National Bank

Disc Medicine price target raised to $153 from $132 at Cantor Fitzgerald

Target:$153.00

+62.4%from $94.19

Oct 17, 2025Raymond James

Disc Medicine price target raised to $108 from $89 at Raymond James

Target:$108.00

+45.2%from $74.36

Oct 17, 2025Wedbush

Disc Medicine price target raised to $110 from $90 at Wedbush

Target:$110.00

+47.9%from $74.36

Nov 5, 2024Scotiabank

Disc Medicine (IRON) PT Raised to $70 at Scotiabank

Target:$70.00

+8.1%from $64.78

Nov 5, 2024BMO Capital

Disc Medicine (IRON) PT Raised to $112 at BMO Capital

Target:$112.00

+77.1%from $63.24

Oct 23, 2024Jefferies

Jefferies Starts Disc Medicine (IRON) at Buy

Target:$89.00

+74.8%from $50.92

Sep 16, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON)

Target:$70.00

+46.5%from $47.79

Aug 22, 2024Wells Fargo

Disc Medicine initiated with an Overweight at Wells Fargo

Target:$75.00

+52.1%from $49.31

Aug 8, 2024Raymond James

Disc Medicine (IRON) PT Raised to $50 at Raymond James

Target:$50.00

+16.7%from $42.85

Jun 17, 2024BMO Capital

Disc Medicine (IRON) PT Raised to $70 at BMO Capital

Target:$70.00

+52.8%from $45.80

May 10, 2024Raymond James

Disc Medicine price target raised to $43 from $40 at Raymond James

Target:$43.00

+43.6%from $29.95

Apr 2, 2024BMO Capital

Disc Medicine (IRON) PT Lowered to $50 at BMO Capital

Target:$50.00

+46.2%from $34.21

Apr 1, 2024Stifel Nicolaus

Disc Medicine (IRON) PT Lowered to $71 at Stifel

Target:$71.00

+107.5%from $34.21

Apr 1, 2024Wedbush

Disc Medicine (IRON) PT Lowered to $43 at Wedbush

Target:$43.00

+34.4%from $32.00

Apr 1, 2024Raymond James

Disc Medicine downgraded to Outperform from Strong Buy at Raymond James

Target:$40.00

+36.1%from $29.40

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance